Hyperprolactinaemia as a side-effect of pressure-lowering treatment with verapamil

Atencion Primaria

Volumn 26, Issue 7, 2000, Pages 510-511

  Ortega Calvo, M ^a   Macias Perez V ^a   Merino Kolly, M N ^b   Torello Iserte J ^b  

^a Zona Basica de Salud de Pilas   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; LUTEINIZING HORMONE; PROGESTERONE; VERAPAMIL;

ADULT; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CASE REPORT; CLINICAL FEATURE; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; HYPERTENSION; LETTER;

EID: 0033670684     PISSN: 02126567     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0212-6567(00)78714-2     Document Type: Letter

References (7)

1. Pathologic hyperprolactinemia
2. Mechanism of verapamil calcium channel blockade induced hyperprolactinemia
3. Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma
4. Hyperprolactinaemia and verapamil: Prevalence and potential association with hypogonadism in men
5. Calcium and prolactin secretion in humans: Effects of the channel blocker, verapamil, in the spontaneous and drug-induced hyperprolactinemia
6. Verapamil acute administration: A new dynamic test in hyperprolactinemic states